INBS
Intelligent Bio Solutions Inc.
There isn't enough reported data to score INBS yet.
UNH
UnitedHealth Group Incorporated
UNH's fundamentals are mixed: free cash flow grew 31%, but earnings per share fell 8.5%. At 23x earnings, it's trading right at its usual valuation. Analysts expect strong earnings growth, though they disagree widely on how much.
INBS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Under pressure | |
| Weak | |
| Unavailable |
INBS's revenue is currently strong, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
UNH Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Healthy | |
| Healthy |
UNH's cash flow and balance sheet are currently healthy, and its revenue and profitability are stable.
INBS PE Valuation
INBS has no meaningful PE right now: it lost money over the past year.
UNH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 18x | $405 | — |
| Cheap | 19x | $325 | -20% |
| Fair | 23x | $410 | +1.2% |
| Current | 23x | $405 | — |
| Expensive | 30x | $526 | +30% |
Historical ranges are pointers, not guarantees.
UNH's PE is in its fair range at 23x. If earnings grow as analysts expect, today's price would be 18x next year's earnings, in its cheap range.
INBS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong decline | |
| -- | |
| Limited | |
| High |
Analysts expect INBS's losses to grow, with revenue declining.
UNH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Stable | |
| Improving | |
| Moderate | |
| Low |
Analysts expect UNH's earnings to grow and its profitability to improve, with its revenue holding steady. However, they disagree widely on these estimates.
INBS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$8.95 | +$7.55 |
| Q2 2026 | -$11.59 | +$8.41 |
| Q3 2023 | -$1,384.80 | -$84.71 |
| Q2 2023 | -$1,452.00 | -$103.91 |
| Q1 2023 | -$1,273.69 | -$92.14 |
| Q4 2022 | -$803.29 | +$810.26 |
| Q3 2022 | -$1,300.09 | +$313.46 |
INBS is still losing money, but far less than before: $8.95 per share over the past year, against $1,613.55 at its worst in late 2021.
UNH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $22.65 | +29% |
| Q3 2026 | $17.55 | -8.5% |
| Q2 2026 | $15.58 | -33% |
| Q1 2026 | $13.28 | -44% |
| Q4 2025 | $13.23 | -15% |
| Q3 2025 | $19.17 | +25% |
| Q2 2025 | $23.09 | +53% |
| Q1 2025 | $23.89 | +46% |
| Q4 2024 | $15.51 | -35% |
UNH has the edge over INBS on earnings quality, reporting a profit while its opponent remains loss making.
INBS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $1.4M | +25% |
| Q2 2026 | $1.1M | +36% |
| Q1 2026 | $1.1M | +18% |
| Q4 2025 | $896.8K | +21% |
| Q3 2025 | $1.1M | +11% |
| Q2 2025 | $843.9K | +16% |
| Q1 2025 | $902.1K | +9.5% |
| Q4 2024 | $741.1K | -3% |
INBS has the edge over UNH on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -193% | +77 points |
| Q2 2026 | -346% | +21 points |
| Q1 2026 | -278% | +5.2 points |
| Q4 2025 | -294% | +12 points |
| Q3 2025 | -270% | +3.2 points |
| Q2 2025 | -368% | +19 points |
| Q1 2025 | -283% | +76 points |
| Q4 2024 | -306% | -45 points |
INBS's operating margin was −193% last quarter, up 77 points from the same quarter a year ago, near the top of its range since 2020.
UNH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $112.7B | -0.4% |
| Q2 2026 | $112B | +0.4% |
| Q1 2026 | $111.7B | +2% |
| Q4 2025 | $113.2B | +12% |
| Q3 2025 | $113.2B | +12% |
| Q2 2025 | $111.6B | +13% |
| Q1 2025 | $109.6B | +9.8% |
| Q4 2024 | $100.8B | +6.8% |
UNH's revenue has held roughly level: $113B last quarter, about level with the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 5.8% | +2 points |
| Q2 2026 | 7.1% | +2.5 points |
| Q1 2026 | 8.1% | -0.3 points |
| Q4 2025 | 0.3% | -7.4 points |
| Q3 2025 | 3.8% | -4.8 points |
| Q2 2025 | 4.6% | -3.4 points |
| Q1 2025 | 8.3% | +0.4 points |
| Q4 2024 | 7.7% | -0.4 points |
UNH has the edge over INBS on profitability, with a higher operating margin.
INBS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q1 2026 | -$4.3M | -$1.6M |
| Q4 2025 | -$1.6M | +$689K |
| Q3 2025 | -$2.9M | -$530K |
| Q1 2025 | -$2.8M | -$308.8K |
| Q4 2024 | -$2.3M | +$544.4K |
| Q3 2024 | -$2.4M | -$1.1M |
| Q2 2024 | -$2.9M | -$2.4M |
| Q1 2024 | -$2.4M | +$71.9K |
UNH has the stronger cash trend. Its trailing FCF is up 5.2% versus its history, compared with INBS at down 50%.
UNH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $4.3B | -16% |
| Q2 2026 | $10.3B | +63% |
| Q1 2026 | $8.1B | +79% |
| Q4 2025 | $160M | -89% |
| Q3 2025 | $5.1B | -61% |
| Q2 2025 | $6.3B | +6.9% |
| Q1 2025 | $4.6B | +1037% |
| Q4 2024 | $1.5B | +$7.6B |
UNH still generates free cash flow, though less than at its 2022 peak: $22.8B over the past year.
INBS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +94% | +1.5M shares |
| 1 year | +436% | +2.5M shares |
| 3 years | +50551% | +3.1M shares |
INBS has 3M diluted shares, up 436% from a year ago.
UNH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -4M shares |
| 1 year | -0.7% | -6M shares |
| 3 years | -3.6% | -34M shares |
| 5 years | -5.5% | -53M shares |
| Available history | -6.6% | -64M shares |
UNH has the edge over INBS on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $3.4B |
| Q2 2026 | $1.6B |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | $2.5B |
| Q1 2025 | $3B |
| Q4 2024 | $5B |
UNH spent $5B buying back its own shares over the past year, down 52% from the year before.
INBS Net Leverage
INBS's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
UNH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.7x | Healthy |
| Q2 2026 | 1.7x | Healthy |
| Q1 2026 | 2.2x | Moderate |
| Q4 2025 | 2.3x | Moderate |
| Q3 2025 | 1.7x | Healthy |
| Q2 2025 | 1.5x | Healthy |
| Q1 2025 | 1.3x | Healthy |
| Q4 2024 | 1.4x | Healthy |
UNH's net debt is about 1.7 years of its operating earnings (EBITDA), about the same as a year ago.
INBS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 42.1 | Neutral |
| Stochastic | 25.1 | Neutral |
INBS's weekly RSI is 42 (neutral) and its Stochastic is 25 (neutral).
UNH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 56.4 | Neutral |
| Stochastic | 60.0 | Neutral |
UNH's weekly RSI is 56 (neutral) and its Stochastic is 60 (neutral).
INBS PE vs Healthcare Sector
INBS has no meaningful PE right now: it lost money over the past year.
UNH PE vs Healthcare Sector
| Metric | UNH | Sector median | Relative |
|---|---|---|---|
| PE | 23x | 26x | 11% below |
| PE % | 47 | 29 | 18 pts above |
UNH is trading at 23x earnings, a 11% discount to the Healthcare sector's median of 26x.
INBS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.71 | 13% above |
| 20 week MA | $1.98 | 2.5% below |
| 50 week MA | $3.82 | 49% below |
| 100 week MA | $9.38 | 79% below |
| 200 week MA | $95.8 | 98% below |
INBS has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 98% below its 200-week average.
UNH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $394.2 | 2.8% above |
| 20 week MA | $400.5 | 1.2% above |
| 50 week MA | $361.2 | 12% above |
| 100 week MA | $376.0 | 7.8% above |
| 200 week MA | $446.6 | 9.3% below |
UNH has the edge over INBS on trend strength, trading above more of its moving averages.
INBS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $25,320.0 | $25,320.0 | 0% |
| 2021 | $25,320.0 | $3,864.0 | -85% |
| 2022 | $3,864.0 | $686.0 | -82% |
| 2023 | $686.0 | $40.6 | -94% |
| 2024 | $40.6 | $14.3 | -65% |
| 2025 | $14.3 | $4.84 | -66% |
| 2026 YTD | $4.84 | $1.93 | -60% |
INBS has finished every year since 2020 lower, and it's down 60% so far in 2026.
UNH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $296.0 | $340.8 | +15% |
| 2021 | $340.8 | $495.4 | +45% |
| 2022 | $495.4 | $531.3 | +7.3% |
| 2023 | $531.3 | $526.5 | -0.9% |
| 2024 | $526.5 | $510.0 | -3.1% |
| 2025 | $510.0 | $331.8 | -35% |
| 2026 YTD | $331.8 | $405.1 | +22% |
UNH has the edge over INBS on returns for 2026, with the stronger performance.